Feinstein Institutes’ Research Journal Molecular Medicine Increases Impact Factor

MANHASSET, N.Y.--(BUSINESS WIRE)--The impact factor of the international peer-reviewed medical research journal Molecular Medicine, which is published by The Feinstein Institutes for Medical Research and Springer Nature’s BioMed Central, rose to 6.354 – the highest score since the publication was founded in 1994.

Peer-reviewed scientific journals are considered the top benchmark for disseminating research to academia and the general public with the aim of improving the way medicine is practiced. An impact factor (IF) or score is a measurement of the importance or rank of a journal and it is used by researchers to determine the reach and influence their published work may have. The annual JCR impact factor is a ratio calculated by dividing the number of current year citations to the source items published in the journal during the previous two years, according to the analytics firm Clarivate.

“Impact factors help inform fellow researchers about the reach and influence a medical journal has on the larger scientific community and why they should consider submitting their studies for publication,” said Betty Diamond, MD, director of the Institute of Molecular Medicine at the Feinstein Institutes and Editor-in-Chief of Molecular Medicine. “We are proud of the team that has helped Molecular Medicine achieve this top mark and I hope that it encourages others to share their science with us.”

Molecular Medicine receives hundreds of research submissions each year. After a rigorous review process, Molecular Medicine publishes about 20 percent of all submitted manuscripts and more than 460,000 papers have been downloaded to date. Molecular Medicine’s most cited review article of 2020 was “Serum amyloid A – a review” by George H. Sack, Jr. from Johns Hopkins University, USA and the most cited research article was "Circular RNA CEP128 acts as a sponge of miR-145-5p in promoting the bladder cancer progression via regulating SOX11” by Zhun Wu and colleagues from First Affiliated Hospital of Xiamen University, Fujian, China.

“Science can only begin to advance when researchers read the foundational work published by others and build upon it with new experiments,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes. “The high impact factor of Molecular Medicine is evidence other leading researchers are turning to this journal as a foundation for important new science.”

In addition to Molecular Medicine, the Feinstein Institutes publishes the journal Bioelectronic Medicine in partnership with BioMed Central, part of Springer Nature.

If you are interested in publishing in Molecular Medicine, researchers can click here to submit their manuscript.

About the Feinstein Institutes

The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.